PolyPid (PYPD) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN IL0011326795
PolyPid financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 USD | 0.00 USD |
| Gross profit | -1.62 m USD | – |
| Operating income | -28.03 m USD | -32.97 m USD |
| EBIT | -27.46 m USD | -33.48 m USD |
| Net income | -29.02 m USD | -34.17 m USD |
| Diluted EPS – continuing operations | -4.91 USD | -2.09 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PolyPid
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
More stocks
- S & Sys Co.,Ltd. (0008Z0.KQ)
- Gem Terminal Industry Co Ltd (2460.TW)
- Next Capital Public Company Limited (NCAP.BK)
- Komplett AS (KOMPL.OL)
- Nextronics Engineering (8147.TWO)
- Biomm S.A (BIOM3.SA)
- Hua Hsu Advanced Technology Co., Ltd. (6682.TWO)
- Dohwa Engin (002150.KS)
- Yuhwa Sec (003460.KS)
- WiSoL CO.LTD (122990.KQ)
- Taurus Armas S.A (TASA3.SA)
- Well Shin Technology Co Ltd (3501.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.